Durect Corp (NASDAQ:DRRX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Durect Corp is a biopharmaceutical company. It develops pharmaceutical products based on two categories which include new chemical entities and drug delivery programs. The lead candidate for the company is DUR-928. Durect Corp has a market cap of $111.820 million; its shares were traded at around $0.69 with and P/S ratio of 3.11.
For the last quarter Durect Corp reported a revenue of $8.04 million, compared with the revenue of $20.75 million during the same period a year ago. For....More>>>